Spark touts animal data for a solution to AAV gene therapy's antibody problem

Amber Tong

Among all the limitations of using an adeno-associated virus as a vector to deliver a gene — still the most established modality in gene therapy given …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Spark touts animal data for a solution to AAV gene therapy's antibody problem

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bay Area biotech VC to shut down 15 months after launch, sources say

Less than two years after blockbuster IPO, Acelyrin merges with Alumis to combine cash, assets

Longtime Sandoz exec announces retirement; Lilly appoints head of India

Bristol Myers prunes pipeline amid new round of cost cuts

Novo Nordisk takes aim at Roche in hemophilia A, but is way behind

Sionna inks $191M IPO for cystic fibrosis pipeline as Aardvark eyes $89M for its own listing

Spark touts an­i­mal da­ta for a so­lu­tion to AAV gene ther­a­py's an­ti­body prob­lem

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Spark touts animal data for a solution to AAV gene therapy's antibody problem